Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.65 |
| ▸ | CTSS | P25774 | 9/20 | 0.65 |
| ▸ | CTSB | P07858 | 3/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 2/20 | 0.53 |
| ▸ | MMP3 | P08254 | 2/20 | 0.53 |
| ▸ | MMP9 | P14780 | 2/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763891 | 0.93 | CTSS (0.75) | CTSKCTSSCTSBCTSLAKT1 | |
| SCHEMBL3758017 | 0.93 | CTSS (0.75) | CTSKCTSSCTSBCTSLAKT1 | |
| SCHEMBL24814567 | 0.86 | MMP3 (0.64) | CTSKCTSSCTSBCTSLMMP1 | |
| SCHEMBL29178423 | 0.86 | MMP3 (0.64) | CTSKCTSSCTSBCTSLMMP1 | |
| SCHEMBL6746907 | 0.86 | CTSS (0.74) | CTSKCTSSCTSBCTSLAKT1 | |
| SCHEMBL3762221 | 0.86 | CTSS (0.74) | CTSKCTSSCTSBCTSLAKT1 | |
| SCHEMBL7300194 | 0.84 | CTSK (0.60) | CTSKCTSSCTSBCTSLMMP1 | |
| SCHEMBL1374859 | 0.84 | CTSK (0.63) | CTSKCTSSCTSBCTSLMMP1 | |
| SCHEMBL346311 | 0.84 | CTSK (0.63) | CTSKCTSSCTSBCTSLMMP1 | |
| SCHEMBL2781406 | 0.84 | CTSK (0.63) | CTSKCTSSCTSBCTSLMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311798-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | HOFFMANN-LA ROCHE, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311798-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | CTSK 2354/4885CTSS 3355/4885CTSB 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.